Each week we bring you information about drugs, techniques, studies and education for your patients and we often find that there are certain things we could learn more about. We had our staff do a survey of recent information requests and found that there were a lot of you who wanted to know more about the DPP-4 inhibitors. You wanted to know about how they worked, how they compared to other diabetes medications, and when your colleagues were selecting them.

We have taken all your suggestions and put them together in this Special Edition newsletter focused solely on DPP-4 inhibitors.

In this Special Edition on DPP-IV Inhibitors, we present a set of our Homerun Slides focused on The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes....

The Mobile Application for Diabetes from Vree gives your patients a full suite of useful tools and provides Interactive Diabetes Education to supplement the advice you give patients, with extensive learning modules that patients can explore at their own pace. Follow this link to find out more and view a video demonstrating all of the features.

Use this convenient Tool for Your Practice to quickly evaluate the best diabetes medications to fit each individual patient. The latest information on DPP-4 inhibitors as well as other diabetes drugs is summed up in this single-page quick-reference chart. Just follow this link to download the complete pdf.

During my frequent visits to prescribers' offices I get a chance to see their prescribing habits. When it comes to DPP-4 inhibitors, medical professionals seem to have similar opinions on how to use each of the drugs from this class. But to test this theory, we contacted 25 primary care physicians, and endocrinologist to get their feedback....

The dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2 diabetes. In clinical practice they are associated with significant reductions in HbA_1c, no weight gain and a low risk of hypoglycemia. Initial cardiovascular safety studies have shown no increase in cardiovascular risk. Indeed, the suggestion of possible cardiovascular benefit seen in the safety studies is now being formally examined in large randomized-controlled trials with primary cardiovascular end points....